For people with diabetic neuropathy, a shoe that feels comfortable may not always be safe. That is the central message behind what DF Blog describes as the “comfort paradox” — the problem that many patients with reduced protective sensation choose footwear based on comfort, even though their ability to detect harmful pressure, friction or poor fit may already be impaired. DF Blog’s original article highlights a new narrative review in the Journal of Clinical Medicine examining footwear use among people with diabetes.
The concern is simple but clinically important: if the foot cannot feel danger, the patient cannot reliably judge whether a shoe is safe.
For podiatrists, CPOs, orthopaedic footwear specialists and diabetic foot teams across India, the Middle East and Africa, this is a critical reminder. Footwear advice for people with diabetes cannot depend only on patient preference or the question, “Does it feel comfortable?”
In healthy feet, discomfort can act as an early warning system. A tight toe box, hard seam, rubbing heel counter or excessive pressure point is usually noticed before it causes serious injury.
In diabetic neuropathy, that warning system may be reduced or absent. A patient may continue walking in a shoe that is too short, too narrow or poorly shaped because it does not cause immediate pain. By the time redness, blistering, callus or ulceration appears, the injury process may already be advanced.
The review cited by DF Blog found that 33% to 82% of people with diabetes may be wearing improperly fitting footwear, with up to 43% wearing shoes that are too short and around 46% wearing shoes that are too narrow.
That finding should concern every diabetic foot service. The problem is not only patient choice. It is the absence of structured footwear assessment, education, fitting and follow-up.
Across IMEA, diabetic foot complications are a major cause of wounds, infection, disability and amputation. Many patients walk long distances, stand for work, wear open sandals or slippers in hot climates, and may not have regular access to podiatry, orthopaedic footwear or CPO-led foot orthotic services.
This makes the “comfort paradox” especially relevant.
In warm countries, sandals and slippers remain popular because they are easy to wear and feel comfortable. But for patients with neuropathy, open or poorly supported footwear can expose the foot to trauma, stones, heat, friction, pressure and accidental injury. A shoe may feel acceptable while still failing to protect the diabetic foot.
IMEA clinicians therefore need to shift the conversation from comfort alone to protective fit.
The DF Blog article describes the goal as a “Goldilocks” fit: not too tight, not too loose. It notes that consensus from the literature suggests clinicians should look for 1–2 cm of clearance between the toes and the end of the shoe, roughly a thumb’s width. It also highlights that while many patients prefer soft cushioning, rigid or rocker soles may be more effective for offloading plantar pressure.
For diabetic foot teams, this means footwear assessment should include:
Comfort should still matter, but it should not be the only measure.
One of the strongest lines in the original article is that clinicians cannot rely on patients to feel whether a shoe fits; the clinician must become the sensor.
This is a useful framework for IMEA practice. The clinician’s role is to detect what the neuropathic foot cannot. That means inspecting the shoe, measuring the foot, checking the insole, reviewing wear marks, looking at skin response, testing protective sensation and explaining risk in simple language.
For CPOs and orthopaedic footwear providers, this also means diabetic footwear should be treated as a clinical intervention, not a retail product. The wrong shoe can contribute to ulceration. The right shoe, insole and offloading strategy can help prevent recurrence and protect mobility.
The International Working Group on the Diabetic Foot has updated guidance on prevention and management of diabetes-related foot disease, including prevention, offloading, infection, classification and Charcot neuro-osteoarthropathy. The 2023 prevention guideline is specifically targeted at clinicians and healthcare professionals involved in preventing foot ulcers in people with diabetes.
For clinics across IMEA, the “comfort paradox” should lead to practical changes in diabetic foot care.
Patients with neuropathy should not be advised to “buy what feels good” without guidance. They need a structured footwear review and a clear explanation of why comfort can be misleading.
Clinics should consider adding a simple footwear check into every diabetic foot visit:
This does not require advanced technology in every setting. Even basic shoe inspection, foot measurement and patient education can reduce risk.
For higher-risk patients, particularly those with previous ulceration, deformity, Charcot foot, partial-foot amputation or recurrent callus, standard footwear may not be enough.
These patients may need:
The goal is not simply to make the shoe feel softer. The goal is to reduce harmful pressure, accommodate deformity, protect skin and support safe walking.
The “comfort paradox” is a powerful concept because it explains a common clinical problem in simple terms. Patients with neuropathy often choose footwear based on a sensation they can no longer fully trust.
For IMEA CPOs, podiatrists and diabetic foot teams, the message is clear: footwear assessment must be objective, structured and repeated. Comfort matters, but protection matters more.
A diabetic shoe should not be judged only by how it feels on the first day. It should be judged by fit, pressure distribution, skin response, offloading, durability, patient adherence and long-term ulcer prevention.
In diabetic foot care, the safest shoe is not always the one that feels best. It is the one that protects the foot the patient can no longer fully feel.